JP2023520405A5 - - Google Patents
Info
- Publication number
- JP2023520405A5 JP2023520405A5 JP2022559594A JP2022559594A JP2023520405A5 JP 2023520405 A5 JP2023520405 A5 JP 2023520405A5 JP 2022559594 A JP2022559594 A JP 2022559594A JP 2022559594 A JP2022559594 A JP 2022559594A JP 2023520405 A5 JP2023520405 A5 JP 2023520405A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- guanine
- cytosine
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025272734A JP2026048940A (ja) | 2020-03-30 | 2025-12-22 | 改変ペプチド核酸組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002326P | 2020-03-30 | 2020-03-30 | |
| US63/002,326 | 2020-03-30 | ||
| PCT/US2021/025019 WO2021202621A2 (en) | 2020-03-30 | 2021-03-30 | Modified peptide nucleic acid compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025272734A Division JP2026048940A (ja) | 2020-03-30 | 2025-12-22 | 改変ペプチド核酸組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520405A JP2023520405A (ja) | 2023-05-17 |
| JP2023520405A5 true JP2023520405A5 (https=) | 2024-08-20 |
| JP7796038B2 JP7796038B2 (ja) | 2026-01-08 |
Family
ID=77921451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559594A Active JP7796038B2 (ja) | 2020-03-30 | 2021-03-30 | 改変ペプチド核酸組成物 |
| JP2025272734A Pending JP2026048940A (ja) | 2020-03-30 | 2025-12-22 | 改変ペプチド核酸組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025272734A Pending JP2026048940A (ja) | 2020-03-30 | 2025-12-22 | 改変ペプチド核酸組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20210309997A1 (https=) |
| EP (1) | EP4127228A4 (https=) |
| JP (2) | JP7796038B2 (https=) |
| AU (1) | AU2021246046A1 (https=) |
| CA (1) | CA3173015A1 (https=) |
| WO (1) | WO2021202621A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021246046A1 (en) | 2020-03-30 | 2022-10-13 | Neubase Therapeutics, Inc. | Modified peptide nucleic acid compositions |
| US20240132628A1 (en) * | 2020-12-15 | 2024-04-25 | Neubase Therapeutics, Inc. | Oligonucleotide analogue therapeutics for treatment of neuromuscular disease |
| US20250360158A1 (en) * | 2022-06-13 | 2025-11-27 | Neubase Therapeutics, Inc. | Oligonucleotide analogue formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080038783A1 (en) * | 2006-06-29 | 2008-02-14 | Applera Corporation | Compositions and Methods Pertaining to Guanylation of PNA Oligomers |
| SI2049664T1 (sl) | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| US7960360B2 (en) | 2006-11-13 | 2011-06-14 | Jennifer Rubin Grandis | Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents |
| CA2732343C (en) * | 2008-07-29 | 2017-05-09 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
| WO2015172058A1 (en) | 2014-05-08 | 2015-11-12 | Carnegie Mellon University | Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor |
| EP3727435B1 (en) * | 2017-12-21 | 2026-02-18 | Carnegie Mellon University | Bivalent nucleic acid ligands and uses therefor |
| WO2020172664A1 (en) * | 2019-02-22 | 2020-08-27 | Carnegie Mellon University | Tuning binding cooperativity in nucleic acid targeting compounds |
| AU2021246046A1 (en) | 2020-03-30 | 2022-10-13 | Neubase Therapeutics, Inc. | Modified peptide nucleic acid compositions |
-
2021
- 2021-03-30 AU AU2021246046A patent/AU2021246046A1/en active Pending
- 2021-03-30 EP EP21781683.4A patent/EP4127228A4/en active Pending
- 2021-03-30 WO PCT/US2021/025019 patent/WO2021202621A2/en not_active Ceased
- 2021-03-30 CA CA3173015A patent/CA3173015A1/en active Pending
- 2021-03-30 US US17/218,145 patent/US20210309997A1/en not_active Abandoned
- 2021-03-30 JP JP2022559594A patent/JP7796038B2/ja active Active
- 2021-04-15 US US17/231,997 patent/US20210324012A1/en not_active Abandoned
- 2021-04-15 US US17/232,001 patent/US11603530B2/en active Active
- 2021-04-15 US US17/232,000 patent/US20220112238A1/en not_active Abandoned
- 2021-04-15 US US17/231,998 patent/US20210309700A1/en not_active Abandoned
-
2023
- 2023-01-27 US US18/102,415 patent/US20230174985A1/en active Pending
-
2025
- 2025-12-22 JP JP2025272734A patent/JP2026048940A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189864A5 (https=) | ||
| JP2023520405A5 (https=) | ||
| JP2021100937A5 (https=) | ||
| CN1116870C (zh) | 司立吉林在制备用于预防或治疗外周神经病的药物中的应用 | |
| JP2023002662A5 (https=) | ||
| JP2009508955A5 (https=) | ||
| JP2013545730A5 (https=) | ||
| JP2022525149A5 (https=) | ||
| JP2004502638A5 (https=) | ||
| US20120027718A1 (en) | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis | |
| JPH06102622B2 (ja) | 肥満の治療 | |
| JP2005526833A5 (https=) | ||
| JPWO2020004675A5 (https=) | ||
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2021534160A5 (https=) | ||
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| JP2023548429A5 (https=) | ||
| JP2023502053A5 (https=) | ||
| JP2022501364A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2025509830A5 (https=) | ||
| JP2014522414A5 (https=) | ||
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| JP2023531930A5 (https=) | ||
| RU2002102076A (ru) | Фармацевтическая композиция, содержащая сибутрамин и орлистат |